Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Long-acting protein drugs for the treatment of ocular diseases.

Ghosh JG, Nguyen AA, Bigelow CE, Poor S, Qiu Y, Rangaswamy N, Ornberg R, Jackson B, Mak H, Ezell T, Kenanova V, de la Cruz E, Carrion A, Etemad-Gilbertson B, Caro RG, Zhu K, George V, Bai J, Sharma-Nahar R, Shen S, Wang Y, Subramanian KK, Fassbender E, Maker M, Hanks S, Vrouvlianis J, Leehy B, Long D, Prentiss M, Kansara V, Jaffee B, Dryja TP, Roguska M.

Nat Commun. 2017 Mar 23;8:14837. doi: 10.1038/ncomms14837.

2.

Numerical comparison of iodine-based and indium-based antibody biodistributions.

Williams LE, Wu AM, Kenanova VE, Olafsen T, Yazaki PJ.

Cancer Biother Radiopharm. 2014 Apr;29(3):91-8. doi: 10.1089/cbr.2013.1564. Epub 2014 Jan 20.

PMID:
24443889
3.

Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.

Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I.

J Biol Chem. 2012 Jun 29;287(27):22927-37. doi: 10.1074/jbc.M112.355131. Epub 2012 May 8.

4.

Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS.

EJNMMI Res. 2011 Nov 7;1(1):24. doi: 10.1186/2191-219X-1-24.

5.

CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS.

Int J Mol Imaging. 2011;2011:834515. doi: 10.1155/2011/834515. Epub 2011 Sep 6.

6.

Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer.

Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS.

J Surg Res. 2011 Oct;170(2):169-78. doi: 10.1016/j.jss.2011.03.065. Epub 2011 Apr 20.

PMID:
21601881
7.

Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning.

Olafsen T, Young SG, Davies BS, Beigneux AP, Kenanova VE, Voss C, Young G, Wong KP, Barnes RH 2nd, Tu Y, Weinstein MM, Nobumori C, Huang SC, Goldberg IJ, Bensadoun A, Wu AM, Fong LG.

J Biol Chem. 2010 Dec 10;285(50):39239-48. doi: 10.1074/jbc.M110.171041. Epub 2010 Sep 30.

8.

Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.

Kenanova VE, Olafsen T, Salazar FB, Williams LE, Knowles S, Wu AM.

Protein Eng Des Sel. 2010 Oct;23(10):789-98. doi: 10.1093/protein/gzq054. Epub 2010 Aug 28.

9.

Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging.

Barat B, Kenanova VE, Olafsen T, Wu AM.

Mol Imaging Biol. 2011 Jun;13(3):526-535. doi: 10.1007/s11307-010-0375-0.

10.

A differential cell capture assay for evaluating antibody interactions with cell surface targets.

Sherman DJ, Kenanova VE, Lepin EJ, McCabe KE, Kamei K, Ohashi M, Wang S, Tseng HR, Wu AM, Behrenbruch CP.

Anal Biochem. 2010 Jun 15;401(2):173-81. doi: 10.1016/j.ab.2010.02.015. Epub 2010 Feb 21.

11.

ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM.

Protein Eng Des Sel. 2010 Apr;23(4):243-9. doi: 10.1093/protein/gzp081. Epub 2010 Jan 6.

12.

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM.

J Nucl Med. 2009 Sep;50(9):1500-8. doi: 10.2967/jnumed.108.060426. Epub 2009 Aug 18.

13.

Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging.

Kenanova V, Barat B, Olafsen T, Chatziioannou A, Herschman HR, Braun J, Wu AM.

Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):104-14. doi: 10.1007/s00259-008-0921-z. Epub 2008 Aug 22.

14.

Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.

Andersen JT, Justesen S, Fleckenstein B, Michaelsen TE, Berntzen G, Kenanova VE, Daba MB, Lauvrak V, Buus S, Sandlie I.

FEBS J. 2008 Aug;275(16):4097-110. doi: 10.1111/j.1742-4658.2008.06551.x. Epub 2008 Jul 15.

15.
16.

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.

17.

A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.

Ferl GZ, Kenanova V, Wu AM, DiStefano JJ 3rd.

Mol Cancer Ther. 2006 Jun;5(6):1550-8.

18.

Tailoring antibodies for radionuclide delivery.

Kenanova V, Wu AM.

Expert Opin Drug Deliv. 2006 Jan;3(1):53-70. Review.

PMID:
16370940
19.

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM.

Cancer Res. 2005 Jul 1;65(13):5907-16.

20.

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2005 Jan 15;65(2):622-31.

Supplemental Content

Loading ...
Support Center